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Abstract
Recent studies have linked expression of lectin-like ox-LDL receptor 1 (OLR1) to tumorigenesis. We analyzed microarray data
from Olr1 knockout (KO) and wild type (WT) mice for genes involved in cellular transformation and evaluated effects of OLR1
over-expression in normal mammary epithelial cells (MCF10A) and breast cancer cells (HCC1143) in terms of gene
expression, migration, adhesion and transendothelial migration. Twenty-six out of 238 genes were inhibited in tissues of
OLR1 KO mice; the vast majority of OLR1 sensitive genes contained NF-kB binding sites in their promoters. Further studies
revealed broad inhibition of NF-kB target genes outside of the transformation-associated gene pool, with enrichment
themes of defense response, immune response, apoptosis, proliferation, and wound healing. Transcriptome of Olr1 KO mice
also revealed inhibition of de novo lipogenesis, rate-limiting enzymes fatty acid synthase (Fasn), stearoyl-CoA desaturase
(Scd1) and ELOVL family member 6 (Elovl6), as well as lipolytic phospholipase A2 group IVB (Pla2g4b). In studies comparing
MCF10A and HCC1143, the latter displayed 60% higher OLR1 expression. Forced over-expression of OLR1 resulted in
upregulation of NF-kB (p65) and its target pro-oncogenes involved in inhibition of apoptosis (BCL2, BCL2A1, TNFAIP3) and
regulation of cell cycle (CCND2) in both cell lines. Basal expression of FASN, SCD1 and PLA2G4B, as well as lipogenesis
transcription factors PPARA, SREBF2 and CREM, was higher in HCC1143 cells. Over-expression of OLR1 in HCC1143 cells also
enhanced cell migration, without affecting their adherence to TNFa-activated endothelium or transendothelial migration.
On the other hand, OLR1 neutralizing antibody inhibited both adhesion and transmigration of untreated HCC1143 cells. We
conclude that OLR1 may act as an oncogene by activation of NF-kB target genes responsible for proliferation, migration and
inhibition of apoptosis and de novo lipogenesis genes.
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Introduction
OLR1, a lectin-like scavenger receptor, is highly conserved in
mammals [1] and it is capable of recognizing several ligands
including the protein moiety of oxidized-LDL (ox-LDL), advanced
glycation end-products, gram-positive and gram-negative bacteria
and apoptotic cells [2]. OLR1 is primarily expressed in vascular
cells and vasculature-rich organs [3], and its activation by a wide
range of stimuli indicative of dyslipidemia, inflammation and dam-
age initiates several signaling cascades including MAPKs, other
protein kinases as well as transcription factors NF-kB and AP-1
[4,5].
Overexpression of OLR1 has been shown in cellular components
of atherosclerotic lesions [6]. Deletion of Olr1 in Ldlr knockout
(KO) mice results in much smaller atherosclerotic lesions asso-
ciated with a drastic reduction of inflammation in the aortic wall
[7]. Olr1 abrogation also attenuates angiotensin II-induced hyper-
tension [8]. Similarly, abrogation of Olr1 reduces the extent of
ischemia/reperfusion injury [9].
An association between obesity and atherosclerotic disease states
in humans is well established [10,11]. Associations with obesity
have been found for various cancers, including breast and prostate
neoplasms [12,13], suggesting a mechanistic overlap in the patho-
biology of atherogenesis and tumorigenesis. Recently, Olr1, acting
through NF-kB mediated inflammatory signaling, was strongly
implicated in carcinogenesis [14].
The focus of the present study was to further elucidate role of
OLR1 as an oncogene based on the premise that as a sensor of
dyslipidemia and a molecule involved in NF-kB activation, OLR1
may be a link between dyslipidemia and cancer. The first part of
the study was based on microarray analysis of wild-type (WT) and
olr1 KO mice. The second part defines the relationship between
olr1 and apoptosis and lipogenesis genes in breast cancer cell line
HCC1143 and migration and adhesion of these cells.
Results
Comparison of OLR1 KO and transformation
transcriptomes
The principal findings from the analysis of microarray data
from the hearts of wild-type (WT) and Olr1 KO from our group
have been reported elsewhere [15]. An additional analysis against
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.the overlapping set of genes (n=238) found to be upregulated
during transformation of two isogenic cell types [14] revealed that
26 genes from this list were inhibited in the Olr1 KO transcriptome
by at least 20% (Table 1). Among these were various components
of immune response (Isg20, C1s, S1r, Ifrd1) and a number of
transcription factors including well-known oncogenes (JunB, Rel,
Irf2, Crem). Promoter analysis of resulting set of genes [16] iden-
tified their enrichment for NF-kB binding sites (p,0.03) which
were located within 500 nucleotides proximal to transcriptional
start sites in all but one (C1s) Olr1 sensitive genes (n=25, Fig. 1).
OLR1 deletion results in a broad inhibition of NF-kB
target genes
Further search for NF-kB regulated genes using a list compiled
from available web based databases and the literature revealed
that inhibition of the p65 subunit observed in the Olr1 KO
transcriptome was complemented with upregulation of inhibitory
Ikba subunit (1.36 fold, p=0.002, Table 1) and accompanied by
significant downregulation of several (n=61) NF-kB target genes
(Table 2). The combined set of Olr1 sensitive NF-kB target genes
displayed enrichment for regulation of apoptosis (p=0.0002),
proliferation (p=0.00003), wound healing (p=0.0002), defense
response (p=0.0011), immune response (p=0.0003) and cell
migration (p=0.0009) (Figure 1). Among the genes involved in
apoptosis (n=11) and cellular proliferation (n=12), 6 and 5,
respectively, were negative regulators (David Bioinformatics
Database, 17).
OLR1 deletion suppresses lipogenesis genes
The microarray findings were validated for select genes using
quantitative real-time PCR. For most of the tested genes, the
transcriptional shifts in Olr1 KO observed in microarrays were
Table 1. A list of transformation related genes influenced by Olr1 deletion in mice.
Gene REFSEQ ID Symbol Fold change P value
Inhibited
interferon-stimulated protein NM_020583 Isg20 23.26 0.007
matrix metallopeptidase 3 NM_0011135271 Mmp3 22.05 0.014
reticuloendotheliosis oncogene NM_009044 Rel 22.02 0.011
complement component 1, s subcomponent NM_144938 C1s 21.76 0.008
complement component 1, r subcomponent NM_023143, C1r 21.61 0.001
suppressor of cytokine signaling 3 NM_007707 Socs3 21.57 0.003
Jun-B oncogene NM_008416 Junb 21.56 0.0009
interferon regulatory factor 2 NM_008391 Irf2 21.51 0.044
fibroblast activation protein NM_007986 Fap 21.44 0.005
synaptosomal-associated protein 23 NM_009222 Snap23 21.41 0.033
N-myc (and STAT) interactor NM_001141949 Nmi 21.41 0.0019
cAMP responsive element modulator NM_013498 Crem 21.40 0.043
pentraxin related gene NM_008987 Ptx3 21.38 0.052
MAPK kinase kinase 7 interacting protein 2 NM_138667 Map3k7ip2 21.37 0.041
TNF receptor superfam. member 21 NM_178589 Tnfrsf21 21.35 0.011
Acetylglucosamine (GlcNAc) transferase NM_139144 Ogt 21.35 0.002
Ras-GTPase-activating protein SH3-domain binding protein 1 NM_013716 G3bp1 21.35 0.003
Rho family GTPase 3 NM_028810 Rnd3 21.31 0.013
interferon-related developmental regulator 1 NM_013562 Ifrd1 21.29 0.026
oxidation resistance 1 NM_130885 Oxr1 21.29 0.003
solute carrier family 2 member 3 NM_011401 Slc2a3 21.28 0.044
annexin A7 NM_009674 Anxa7 21.28 0.001
karyopherin (importin) alpha 2 NM_010655 Kpna2 21.27 0.014
prostaglandin-endoperoxide synthase 1 NM_008969 Ptgs1 21.26 0.031
lectin, galactose binding, soluble 8 NM_018886 Lgals8 21.20 0.014
Stimulated
ser (or cys) peptidase inhibitor, clade. E, memb 2 NM_009255 Serpine2 1.26 0.018
succinate dehydrogenase complex, subunit C NM_025321 Sdhc 1.29 0.017
E26 avian leukemia oncogene 2, 39 domain NM_011809 Ets2 1.35 0.001
NF-k light polypeptide gene enhancer in B-cells inhibitor, alpha NM_010907 Nfkbia 1.36 0.002
GTP binding protein 2 NM_001145979 Gtpbp2 1.41 0.008
mitogen-activated protein kinase kinase kinase 5 NM_008580 Map3k5 1.51 0.005
SRY-box containing gene 4 NM_009238 Sox4 1.54 0.007
doi:10.1371/journal.pone.0020277.t001
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inhibition of key enzymes for lipogenesis (Figure 2B), including
ATP citrate lyase (Acly), acetyl-Coenzyme A carboxylase alpha
(Acaca), fatty acid synthase (Fasn), stearoyl-CoA Desaturase 1 (Scd1)
and ELOVL family member 6 (Elovl6). It is of interest that none of
the Olr1-sensitive lipid metabolism related genes carried NF-kB
binding sites in their promoters. This suggests that the effects of
Olr1 on lipogenesis may be independent from its NF-kB signaling
arm. On the other hand, several lipid metabolism transcription
factors, including sterol regulatory element binding factor 2
(Srebf2), cAMP responsive element modulator (Crem), peroxisome
proliferator activated receptors alpha and gamma (Ppara and
Pparg), as well as CCAAT/enhancer binding protein (C/EBP)
beta, were found to be downregulated in Olr1 KO mice
(Figure 2B).
Effects of OLR1 overexpression in normal epithelial and
cancer cells
Transfection of MCF10A and HCC1143 cells with OLR1 ex-
pression vector resulted in 5 to 8-fold increase of OLR1 expression,
which falls within the range OLR1 upregulation. In epithelial cells
exposed to ox-LDL [18]. This led to modest upregulation of RELA
(p65) and significant increases in RNA message for BCL2, BCL2A1,
TNFAIP3 and CCND2 (Figure 3B). Compared to MCF10A cells,
HCC1143 cells displayed increased basal levels of OLR1 (59%,
p,0.05), FASN (24%, p,0.03), SCD1 (21%, p,0.01) and
PLA2G4B (153%, p,0.01) (Figure 3C). The response from
lipogenesis genes to OLR1 transfection varied in these cell lines
(Figure 3D). In MCF10A cells, over-expression of OLR1 sig-
nificantly stimulated transcription of SCD1 (37%, p,0.02),
ELOVL6 (38%, p,0.05) and PLA2G4B (153%, p,0.02) concom-
itant with upregulation of CREM, whereas in HCC1143 cells
CREM transcription declined and SCD1 and PLA2G4B were
inhibited compared with control cultures transfected with empty
vector.
Over-expression of OLR1 facilitates wound healing, but
has no effect on adhesion
It has been reported that inhibition of OLR1 using siRNAs
resulted in reduction of tumor growth in vivo and cancer cell
migration in vitro [14]. In order to evaluate effects of OLR1
upregulation, we transfected HCC1143 cells with either empty
plasmid or OLR1 expression vector and tested migration in a
wound healing assay (Figure 4A). Over-expression of OLR1 was
confirmed using qPCR. Cells with upregulated OLR1 bridged the
wounds much faster than control cultures (p,0.001). In contrast,
adhesion and transendothelial migration of OLR1 transfected
cancer cells did not differ from control values (not shown).
However, basal adhesion and transendothelial migration of
non-transfected HCC1143 cells were significantly attenuated
when OLR1 was inhibited or neutralized in endothelial cells
using siRNA or pre-treating cells with OLR1 neutralizing antibody
(Figure 4BC).
Discussion
This study suggests multiple potential links between OLR1 and
susceptibility to cancer. First, the microarray database in the mice
with Olr1 abrogation exhibited a marked reduction in expression
of NF-kB target genes involved in cellular transformation [14], as
well as genes related to lipogenesis. Second, over-expression of
OLR1 in a human cancer cell line showed significant upregulation
of several genes with oncogenic properties and a significant in-
crease in cell migration.
Our microarray analysis showed that the vast majority of genes
reported to be upregulated during cell transformation (but
inhibited in Olr1 KO mice) carried NF-kB binding sites in their
promoters (Table 1). Furthermore, a significant portion of NF-kB
target genes outside of the transformation-related pool, especially
those involved in regulation of apoptosis, proliferation and
migration, were also down-regulated in the Olr1 KO transcrip-
tome (Table 2). In the mouse Olr1 KO microarray, both B-cell
leukemia/lymphoma 2 related protein A1 (Bcl2a1) and Bcl2 were
transcriptionally inhibited. Bcl2a1 is an upstream negative reg-
ulator of the mitochondriocentric mode of apoptosis via prevention
of cytochrome c release into the cytoplasm, which is required for
initiation of the apoptotic cascade. It has been reported that
enhanced synthesis of BCL2A1 and BCL-XL are the underlying
cause of about 1000-fold greater resistance of subsets of chronic
lymphocytic leukemia cells [19]. TNFa-induced protein 3
(TNFAIP3) is a key regulator of inflammation and immunity
Figure 1. Olr1 deletion results in broad inhibition of NF-kB target genes. A diagram depicting a set of overlapping genes between
transformation and Olr1 KO transcriptomes. From the set of 238 genes upregulated during transformation, 26 genes were found to be inhibited in
Olr1 KO mice. Vast majority of these genes carried NF-kB sites in their proximal promoter sequences. In total, 86 NF-kB target genes were found to be
inhibited in Olr1 KO mice with enrichment for regulation of apoptosis (p=0.0002), proliferation (p=0.00003), wound healing (p=0.0002), defense
response (p=0.0011), immune response (p=0.0003) and cell migration (p=0.0009).
doi:10.1371/journal.pone.0020277.g001
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Gene Title Gene Symbol
a Fold change P value A W P D M
colony stimulating factor 2 Csf2
1,2 -3.55 0.0148 
phospholipase A2, group IVB (cytosolic) Pla2g4b
1 -3.29 0.0079
lectin, galactose binding, soluble 3 Lgals3
1 -2.93 0.0302
BCL 2 related protein A1a Bcl2a1
1,2,3 -2.90 0.0304 
chitinase 3-like 1 Chi3l1
2 -2.80 0.0145
lymphotoxin A Lta
1 -2.73 0.0007  
hepcidin antimicrobial peptide Hamp
2 -2.50 0.0518 
immunoglobulin heavy chain complex Igh
2 -2.34 0.0006
glucosaminyl (N-acetyl) transferase 1, core 2 Gcnt1
2 -2.23 0.0216
fos-like antigen 2 Fosl2
2 -2.22 0.0012 
NFkB inhibitor, e Nfkbie
2 -2.20 0.0321
selectin, platelet Selp
1 -2.20 0.0309  
complement factor B Cfb
1 -2.15 0.0079 
deiodinase, iodothyronine, type II Dio2
2 -2.07 0.0039
FBJ osteosarcoma oncogene Fos
2 -2.03 0.0270
interleukin 17A Il17a
2 -2.00 0.0103 
thrombospondin 1 Thbs
2 -1.94 0.0146  
CD3 antigen, gamma polypeptide Cd3g
1 -1.92 0.0020 
LPS-induced TN factor Litaf
3 -1.91 0.0072
CD48 antigen Cd48
1 -1.77 0.0228
prostaglandin E synthase Ptges
2 -1.61 0.0484 
chemokine (C-X-C motif) ligand 5 Cxcl5
1 -1.60 0.0055 
HSP90, a (cytosolic), class A member 1 Hsp90aa1
2 -1.59 0.0355
CD209f antigen Cd209f
2 -1.56 0.0067
vascular cell adhesion molecule 1 Vcam1
1,2 -1.54 0.0007
coagulation factor III F3
1 -1.54 0.0111 
twist gene homolog 1 (Drosophila) Twist1
2 -1.52 0.0092
B-cell leukemia/lymphoma 2 Bcl2
1,2,3 -1.52 0.0201  
cyclin D2 Ccnd2
3 -1.51 0.0161 
dihydropyrimidine dehydrogenase Dpyd
2 -1.48 0.0062
CASP8 and FADD-like apopt. regulator Cflar
1,2,3 -1.44 0.0544 
related RAS viral oncogene homolog 2 Rras2
3 -1.43 0.0476 
CD274 antigen Cd274
2 -1.42 0.0273 
immediate early response 3 Ier3
1,2,3 -1.41 0.0250
Fas (TNFRSF6)-assoc. via death domain Fadd
3 -1.39 0.0272 
TNF, alpha-induced protein 3 Tnfaip3
1,2,3 -1.38 0.0520
Kruppel-like factor 10 Klf10
3 -1.38 0.0267 
NUAK family, SNF1-like kinase, 2 Nuak2
2 -1.37 0.0300 
TNF receptor superfamily, member 21 Tnfrsf21
1 -1.35 0.0113
interferon regulatory factor 7 Irf7
1,2 -1.35 0.0173
transglutaminase 2, C polypeptide Tgm2
1 -1.31 0.0390 
CD82 antigen Cd82
3 -1.31 0.0308
phosphodiesterase 7A Pde7a
2 -1.31 0.0123
heparanase Hpse
2 -1.29 0.0390
ATP-binding cass., subf. B, memb. 1A Abcb1a
1 -1.28 0.0298
midkine Mdk
2 -1.27 0.0502 
MAD homolog 7 (Drosophila) Smad7
3 -1.27 0.0195
solute carrier family 3, member 2 Slc3a2
2 -1.27 0.0355
Proteasome subunit, beta type 9 Psmb9
1,2 -1.25 0.0264
cyclin D binding myb-like TF 1 Dmtf1
2 -1.25 0.0224
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it also desensitizes cells from TNFa-induced cytotoxicity and was
shown to be anti-apoptotic in breast cancer MCF7S1 cells [20].
Inhibition of TNFAIP3 compromises growth and survival of glio-
blastoma stem cells via inhibition of cell cycle progression and NF-
kB activity, and increases survival of mice bearing glioblastome
xenografts [21].
We observed a significant reduction of Ccnd2 message in Olr1
KO mice and its multi-fold upregulation in OLR1 transgenic
HCC1143 cells. Cyclin D2 is a highly conserved regulator of cyclin-
dependent kinases 4 and 6 responsible for of G1/S transition. This
gene is epigenetically silenced in the majority of breast cancers [22].
Its overexpression in LNCaP cells results in an impediment to
proliferation and increased apoptosis [23]. In addition, Olr1
deletion appeared to compromise the entire technological chain
of de novo lipogenesis, including synthesis of saturated C16 and C18
fatty acids (Fasn and Elovl6), and their conversion into MUFAs
(Scd1). Many cancers, including those involving prostate and breast
[24,25], rely almost exclusively on de novo synthesis regardless of
nutritional availability. The switch to de novo lipogenesis occurs early
and is a prerequisite for efficient transformation. Novel effects of
OLR1 on lipid metabolism could account for much of its reported
pro-oncogenic activity. For example, the expression level of FASN
positively correlates with poor cancer prognosis [26], its genomic
amplification is a common occurrence in some cancers [27], and its
over-expression promotes transformation of epithelial cells [28].
Gene Title Gene Symbol
a Fold change P value A W P D M
beta-2 microglobulin B2m
1,2 -1.24 0.0007 
adenosine A1 receptor Adora1
1 -1.23 0.0215  
nuclear receptor subf. 3, gr. C, member 1 Nr3c1
2 -1.22 0.0540 
platelet derived GF, B polypeptide Pdgfb
1,2 -1.22 0.0152 
cAMP responsive element bind. protein 3 Creb3
2 -1.21 0.0306
Legend: (
a)- a list of NFkB target genes was compiled from the following web-based databases: 1 - http://bioinfo.lifl.fr/NF-KB/; 2 -http://people.bu.edu/gilmore/nf-kb/
target/index.html#cyto; and 3 - http://www.broadinstitute.org/mpr/publications/ projects/Lymphoma/ FF_NFKB_suppl_ revised. pdf. The genes whose expression was
significantly altered by OLR1 deletion was analyzed for enrichment themes using DAVID bioinformatic database. The enriched themes included regulation of apoptosis,
‘‘A’’; Wound healing,‘‘W’’; Cell proliferation, ‘‘P’’; Defense response,‘‘D’’; Cell migration, ‘‘M’’.
doi:10.1371/journal.pone.0020277.t002
Table 2. Cont.
Figure 2. qPCR validation of microarray data. A. qPCR validation of select genes from overlapping set (from Table 1); B. Expression of
lipogenesis genes and transcription factors in olr1 KO mice. White bars – microarray data; black bars – qPCR data. All P values,0.05.
doi:10.1371/journal.pone.0020277.g002
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types of cancers, including mammary cancer [29]; its upregulation
is associated with transformation and its knock-down results in
decreased cell proliferation, a loss of anchorage-independent
growth and impaired apoptosis [30]. It is of note that compared
to MCF10A cells, over-expression of OLR1 in HCC1143 cells did
not evoke the expected activation of lipogenesis genes. This may be
explained by maximally increased basal expression of these genes in
HCC1143 cells at baseline (Figure 3D).
As most of the genes upregulated in OLR1-TG HCC1143 cells
are functionally pleiotropic, we evaluated the cumulative outcome
of their upregulation on wound healing, adhesion and transen-
dothelial migration assays (Figure 4). Notably, the migration of
cells was seen to almost double the control value in cells with over-
expression of OLR1, strongly suggesting a role for this molecule in
breast cancer growth. On the other hand, presentation of OLR1 on
the surface of cancer cells did not seem to be essential for adhesion
to activated endothelial cells or for transendothelial migration.
The level of OLR1 in endothelial cells, however, appears to be
important, as addition of neutralizing OLR1 antibody to the
medium or inhibition of OLR1 transcription significantly im-
paired adhesion and transendothelial migration in non-transfected
cancer cells. This is indicative of OLR1 as a possible mechanism of
cancer cell-endothelium interactions, as tumor cells are charac-
terized by abundance of OLR1 ligand phophatidylserine on the
cellular membranes [31].
In summary, our data from multiple approaches in transgenic
mice and human normal epithelial and cancer cell lines suggest
that OLR1 has several pro-oncogenic actions based on: a)
activation of NF-kB signaling pathway resulting in inhibition of
apoptosis and stimulation of proliferation; b) activation of de novo
lipogenesis, and c) more efficient adhesion and transendothelial
migration due to upregulation of OLR1 in endothelium. We
believe these data strongly suggest that OLR1 may function as a
link between obesity and susceptibility to breast cancer.
Materials and Methods
Animals
C57BL/6 mice were obtained from Jackson Laboratories. The
homozygous Olr1 KO mice were developed on C57BL/6
background as described previously [17]. The Olr1 KO mice
showed total absence of Olr1 as determined by RT PCR and
immunostaining, and the binding of oxLDL to the vascular intima
was completely absent in these animals. All animals received
humane care in compliance with the Public Health Service Policy
on Humane Care and Use of Laboratory Animals published by
the National Institutes of Health. The present studies were
Figure 3. Effects of OLR1 overexpression on transcription of genes involved in apoptosis, proliferation and lipogenesis in MCF10a
and HCC1143 cells. These cells were transfected with either empty vector or OLR1 cDNA (Origene, Rockville, MD) using Lipofectamine 2000
(Invitrogen). Transfection efficiency (70–80%) was evaluated using GFP vector. RNA was extracted 48 hours post-transfection, converted into cDNA
and the expression of genes was determined by quantitative PCR. A. Efficiency of transfection (cells transfected with GFP vector). B. Quantitative PCR
plot. Note the enhancement of OLR1 expression in both control and OLR1-transfected cultures in response to ox-LDL. C. Expression of genes
involved in apoptosis and proliferation. In order to stimulate OLR1 associated signaling requiring OLR1-ligand interaction, OLR1 transfected cells were
treated with 40 mg/ml ox-LDL for 24 hours; graphs represent comparison with untreated control cells transfected with empty vector; D. Basal
expression of OLR1, PLA2G4B and lipogenesis genes in normal human mammary epithelial cells (MCF10A) and breast cancer cells (HCC1143); E.
Expression of OLR1, PLA2G4B and lipogenesis genes in MCF10a and HCC1143 cells transfected with OLR1 treated according to the protocol described
above. F. Expression of lipogenesis transcription factors in MCF10a and HCC1143 cells transfected with OLR1 and treated according to the protocol
described above. All experiments were conducted in triplicates. (*) p,0.05 compared to respective control; ({)–p ,0.05 compared to MCF10A.
doi:10.1371/journal.pone.0020277.g003
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number 2484, dated November 2007.
Microarray Analysis
Total RNA of heart was extracted from WT mice and Olr1 KO
mice. Microarray analysis was performed by Affymetrix Mouse
Genome GenChip 430 2.0 gene expression array (Affymetrix Inc.
Santa Clara, CA) and analyzed using Affymetrix Microarray
Analysis Suite (MAS) 5.0 to assess the quality of RNA and
hybridization. A log base 2 transformation was applied to the data
before the arrays were normalized. All values from each array
were normalized to the 75th percentile value of the array, which
was arbitrarily set at intensity minimum .100. For gene ex-
pression annotation, EASE (as described in http://apps1.niaid.
nih.gov/David) analysis was performed on significant genes
identified by one sample t-test. In addition, Gene Ontology
(GO) terms http://www.geneontology.org) for biological processes
and cellular component were identified as proposed by the GO
Consortium. All microarray data is MIAME compliant and that
the raw data has been deposited in a MIAME compliant database
(ArrayExpress) as detailed on the MGED Society website http://
www.mged.org/Workgroups/MIAME/miame.html (accession
number E-MTAB-473).
Reagents and cell lines
All reagents, unless stated otherwise, were purchased from
Sigma (St. Louis, MO). Human breast cancer cell line HCC1143
was a kind gift of Dr. A. Basnakian (University of Arkansas for
Medical Sciences, Little Rock AR). Mammalian expression vector
(pCMV5-XL5) with human OLR1 cDNA were obtained from
Origene (Rockville, MD). Silencer Select Validated siRNA to
OLR1 (s9843) was purchased from Invitrogen (Carlsbad, CA).
Cells were cultured using standard RPMI 1640 growth medium
supplemented with fetal bovine serum (10%) and ampicillin/
streptomycin. High TBAR ox-LDL (90 nmoles MDA/mg
Protein) was purchased from Biomedical Technologies Inc.
(Stoughton, MA). Human IgG was purchased from Abcam
(Cambridge, MA).
Real-Time Quantitative PCR
Cells were transfected with either empty vector or OLR1
expression vector. The efficiency of transfection was confirmed in
parallel experiments with GFP carrying plasmid. Part of the
transfected cultures (all in triplicates) was treated with oxLDL
(40 mg/ml) for 24 hours before harvesting and RNA extraction.
RT qPCR was performed using the Applied Biosystems 7900 real-
time PCR system. qPCR specific primers were designed using
Probe-Finder (http://www.roche-appliedscience.com) web-based
software. All qPCR reactions were carried out in a final volume of
15 ml containing 16of SYBR Green PCR Master Mix (Applied
Biosystems, Carlsbad, CA), 300 nM of each gene specific primers,
100 ng cDNA, in sterile deionized water. The standard cycling
condition was 50uC for 2 min, 90uC for 10 min, followed by 40
cycles of 95uC for 15 s and 62uC for 1 min. The results were
analyzed using SDS 2.3 relative quantification manager software.
The comparative threshold cycles values were normalized for
GAPDH reference genes. qPCR was performed in triplicate to
ensure quantitative accuracy.
Transfection protocol
Cells were transfected with either empty vector or OLR1 cDNA
constructs (Origene, Rockville, MD) using lipofectamine 2000
Figure 4. Phenotypic consequences of OLR1 overexpression or inhibition.A .Wound healing assay. Upper panel - representative images of
wound healing assay performed using HCC1143 cells transfected with either empty plasmid or OLR1 cDNA vector; Lower panel – graph depicting the
distance between edges of the wound after 36 hours of incubation. (*) – p,0.01; B. Adhesion assay. Upper panel- representative images of adherent
non-transfected HCC1143 cells loaded with CellTracker Red CMTX (Invitrogen, Carlbad, CA) and applied to non-activated or activated (50 mg/ml
oxLDL, 4 hrs) confluent HUVECs transfected with OLR1 Silencer or scrambled siRNA. Lower panel - graph depicting the number of adherent cells
averaged from multiple fields of view in triplicate cultures. (*) – p,0.05 compared to non-activated control (‘‘scrRNA’’); ({)-p ,0.05 compared to
scrambled RNA; C. Colorimetric transendothelial migration assay. Upper panel – verification of the confluence of HUVECs on the membranes by
staining cells with CellTracker Red CMTX. Lower panel – absorbance values of stain extracted from the cells migrated through TNFa-activated
endothelial monolayer in presence of OLR1 neutralizing antibody or human IgG (Control).
doi:10.1371/journal.pone.0020277.g004
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instructions with minor modifications. In preliminary experiments,
we determined that higher transfection efficiency is achieved by
applying a 2:1 ratio of DNA to lipofectamine in relation to the
proposed concentration of DNA recommended in the general
protocol. Using these conditions, we routinely observed 70–80%
transfection efficiency. Transfection of HUVECs with OLR1
Silencer (s9843) or scrambled siRNA (Invitrogen, Carlsbad, CA)
was carried out using lipofectamine 2000 according to manufac-
turer’s instructions. Cells we used in adhesion experiments
48 hours post-transfection and inhibition of OLR1 transcription
was verified by quantitative RT PCR.
Wound healing assay
Wound healing assay was performed to determine cell mi-
gration, according to the following protocol: Cells were cultured to
confluence in 24-well plates, and two separate scratch wounds
were made in every well using a sterile 200 ml pipette tip. Cells
lifted in the process of scratching were gently removed by washing
in PBS, then fresh growth medium was added. Pictures were taken
at 106 magnification every 12 hours and the final picture after
36 hours of incubation was taken after loading the cells with
calcein AM (Invitrogen, Carlsbad, CA).
Adhesion assay
Human umbilical vein endothelial cells (HUVECs) were grown
to confluence in 12-well plates and activated by exposure to
oxLDL (50 mg/ml) for 4 hrs. Breast cancer cells HCC1143 were
labeled with CellTracker Red CMTX (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions and added on to endo-
thelial monolayer at concentration of 10
5 cells per well. Plates were
incubated for 1 hour in a CO2 incubator and then gently washed 3
times with growth medium to remove non-adherent cells. The
number of cells attached to endothelium was counted in several
fields of view in triplicate cultures using fluorescent microscope.
Colorimetric transendothelial migration assay
The transmigration potential of HCC1143 cells was evaluated
using QCM Tumor Cell Transendothelial Migration Assay
(Millipore, Billerica, MA) according to manufacturer’s instruc-
tions. Briefly, HUVECs were seeded on fibronectin-coated cell
culture inserts at high density (pore size 8 mm), cultured until
reaching 100% confluence and activated by exposure to 20 ng/ml
TNFa.overnight. Breast cancer cells HCC1143 were added.
(1610
5 per insert) to the monolayer and incubated in the cell
incubator for 6 hours. Upon completion of the incubation period,
growth medium and cells were gently swabbed from the interior of
inserts The extent of transmigration was evaluated by measuring
the amount of stain extracted from transmigrated cells on the
outer surface of the membrane (absorbance at 570 nm) using a
plate reader.
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